Sunil Babu, MD
I am board certified in internal medicine, hematology, and oncology. I am currently heading the clinical research program at FWMOH with special interest in treating lung, breast and pancreatic cancer.
Fellowship in hematology and oncology at New York Medical College, Valhalla, New York
Residency, at New York Medical College, Valhalla, New York
Original training in medicine at St. Paul’s College, India
Board certified in Internal medicine / hematology / oncology
Publications and Clinical Trials Include:
- Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)
- Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation – Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370)
- Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies
- Exceptional Response with Immunotherapy in a Patient with Anaplastic Thyroid Cancer
- Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes
- Predictors and Prevalence of Pain and Its Management in Four Regional Cancer Hospitals in India
- Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153